Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Covington
US Department of Justice
Mallinckrodt
QuintilesIMS
Merck
Harvard Business School
Dow
Baxter
Chubb
McKinsey

Generated: August 23, 2017

DrugPatentWatch Database Preview

NIPENT Drug Profile

« Back to Dashboard

What is the patent landscape for Nipent, and what generic Nipent alternatives are available?

Nipent is a drug marketed by Hospira Inc and is included in one NDA.

The generic ingredient in NIPENT is pentostatin. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the pentostatin profile page.

Summary for Tradename: NIPENT

Patents:0
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list32
Clinical Trials: see list7
Patent Applications: see list9,958
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:NIPENT at DailyMed

Pharmacology for Tradename: NIPENT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Hospira Inc
NIPENT
pentostatin
INJECTABLE;INJECTION020122-001Oct 11, 1991APRXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: NIPENT

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Hospira Inc
NIPENT
pentostatin
INJECTABLE;INJECTION020122-001Oct 11, 1991► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Cipla
Daiichi Sankyo
Merck
Boehringer Ingelheim
Harvard Business School
Cerilliant
Novartis
McKesson
Federal Trade Commission
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot